trending Market Intelligence /marketintelligence/en/news-insights/trending/hAu_-FUnKDsFN_hXj9DJ3A2 content esgSubNav
In This List

Intellipharmaceutics, Purdue Pharma get stay in patent infringement lawsuit

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Intellipharmaceutics, Purdue Pharma get stay in patent infringement lawsuit

Intellipharmaceutics International Inc. said its ongoing lawsuits with affiliates of Purdue Pharma LP have been stayed after Purdue filed for a bankruptcy stay.

Toronto-based Intellipharmaceutics was defending allegations that its pain relief drug Rexista infringed on patents owned by Purdue.

The patent infringement lawsuit is under a stay until March 2, 2020.

Purdue filed for bankruptcy protection in September after it reached a deal with state officials to settle its alleged involvement in the U.S. opioid epidemic.

The Stamford, Conn.-based maker of painkiller OxyContin said it will provide more than $10 billion in funding for life-saving opioid overdose reversal medications such as nalmefene and naloxone, which will be provided by a newly established entity called NewCo at zero to low cost, to help address the crisis.